Number of the records: 1

certolizumab pegol

SYS		d000068582
LBL		00000nz--a2200181n--4500
005		20250606221736.9
008		160101\|\|\|anznnbabn-----------\|-a\|a------
040		$b slo $a BA006 $d BA006
065		$a D05.750.741.125
065		$a D12.644.541.500.650.250
065		$a D12.776.124.486.485.114.224.060.500
065		$a D12.776.124.486.485.680.650.250
065		$a D12.776.124.790.651.114.224.060.500
065		$a D12.776.124.790.651.680.650.250
065		$a D12.776.377.715.548.114.224.200.500
065		$a D12.776.377.715.548.680.650.250
066		$a 01 $c 03
150		$a certolizumab pegol $x AD $x AE $x AN $x BI $x BL $x CF $x CH $x CL $x DE $x EC $x GE $x HI $x IM $x IP $x ME $x PD $x PH $x PK $x PO $x RE $x TO $x TU $x UL $x UR $2 slo
450		$w v $a CDP870 $2 slo
550		$7 sllk_us_auth*d014409 $Y Tumor Necrosis Factor-alpha $w b $a faktor nekrotizujúci nádory, alfa
550		$7 sllk_us_auth*d007166 $Y Immunosuppressive Agents $w P $a imunosupresíva
550		$7 sllk_us_auth*d018501 $Y Antirheumatic Agents $w P $a antireumatiká
550		$7 sllk_us_auth*d000079424 $Y Tumor Necrosis Factor Inhibitors $w P $a inhibítory faktora nekrotizujúceho nádory
550		$7 sllk_us_auth*d014409 $Y Tumor Necrosis Factor-alpha $w p $a faktor nekrotizujúci nádory, alfa
665		$a 2016 (2003) $2 eng
680	9-	$i A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS. $2 eng
750	-2	$a Certolizumab Pegol $2 eng
980		$x M

Number of the records: 1